← Back to Search

Exercise Regimen for Breast Cancer

N/A
Waitlist Available
Led By Karen Milligan, MD
Research Sponsored by Nevada Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Requires treatment that includes chemotherapy, radiation therapy or both chemotherapy and radiation therapy
Women aged 18 and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will compare the outcomes of two groups, one of which will receive a physical activity intervention while the other will only receive limited information on activity.

Who is the study for?
This trial is for women over 18 with Stage 0 to III breast cancer, diagnosed before treatment. Participants must need chemo or radiation therapy and be fit enough for exercise as determined by the study team. They can't join if they have advanced cancer, started treatment already, don't need chemo or radiation, are pregnant/lactating, have certain chronic diseases or recent major surgery.Check my eligibility
What is being tested?
The study tests an exercise program starting at diagnosis and continuing through treatment into six months of survivorship against a control group that receives basic activity information. The goal is to compare physical outcomes between those who follow the regimen and those who do not.See study design
What are the potential side effects?
While specific side effects aren't listed for exercising during cancer treatment in this summary, common concerns may include fatigue, muscle soreness, joint pain or increased risk of injury. Any unusual symptoms should be reported to the research team.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I need treatment that involves chemotherapy, radiation, or both.
Select...
I am a woman aged 18 or older.
Select...
My breast cancer is between stage 0 and III and I haven't started treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in CRP
Secondary outcome measures
Change in body composition
Change in laboratory values
Overall Survival
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention GroupExperimental Treatment1 Intervention
Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
Group II: Control GroupActive Control1 Intervention
The control group will receive basic information on physical activity but not be instructed.

Find a Location

Who is running the clinical trial?

VonsUNKNOWN
Nevada Cancer InstituteLead Sponsor
5 Previous Clinical Trials
64 Total Patients Enrolled
Karen Milligan, MDPrincipal InvestigatorNevada Cancer Institute

Media Library

Exercise Regimen Clinical Trial Eligibility Overview. Trial Name: NCT01157130 — N/A
Breast Cancer Research Study Groups: Control Group, Intervention Group
Breast Cancer Clinical Trial 2023: Exercise Regimen Highlights & Side Effects. Trial Name: NCT01157130 — N/A
Exercise Regimen 2023 Treatment Timeline for Medical Study. Trial Name: NCT01157130 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being enrolled in this experiment?

"No, this particular study is not currently looking for participants. Although, it is important to note that there are 2,373 other clinical trials that are presently recruiting patients."

Answered by AI
~7 spots leftby Mar 2025